Neurogene Appoints Stuart Cobb, Ph.D. as Chief Scientific Officer
Appointment bolsters Neurogene’s mission to bring life-changing therapies to patients with rare neurological disorders
NEW YORK, January 23, 2019 – Neurogene, Inc., a new company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced that Stuart Cobb, Ph.D., will serve as Chief Scientific Officer.
Dr. Cobb brings over 20 years of experience in translational neuroscience. He will be leading Neurogene’s scientific research, including developing our scientific strategy to support our existing and growing gene therapy portfolio, as well as identifying novel technologies that complement our pipeline.
Dr. Cobb will divide his time equally between Neurogene and the University of Edinburgh, where he is currently a Simons Fellow and Reader in Neuroscience and will continue to lead his research team. He will also continue to directly support patient groups through his contributions to various professional advisory boards of rare disease foundations.
Dr. Cobb has a B.Sc. from the University of Glasgow and a Ph.D. in neuroscience from the University of Oxford, UK. He was a Caledonian Research Fellow and has led academic research laboratories at the Universities of Glasgow and Edinburgh. His research is focused on developing novel genetic treatments for brain disorders based on a deep understanding of the molecular and cellular pathology. His work, which has been published in leading journals such as Science and Nature, includes seminal work on the inherent reversibility of neurological features in neurodevelopmental disease.
“I am thrilled to be joining Neurogene at this exciting time,” said Dr. Cobb. “I have been immensely impressed by the passion for high quality science and innovation which lies at the heart of Neurogene and which will lead the way to transformative therapies across devastating brain disorders. I am excited to join my new colleagues in driving forward these programs and extending the portfolio into novel genetic indications.”
“I am pleased that Stuart Cobb will be leading our scientific efforts and confident he will bring substantial leadership to our evolving portfolio,” said Rachel McMinn, Ph.D., President and Chief Executive Officer. “He has focused his scientific career on understanding aberrant early brain development leading to neurodevelopmental disorders and applying novel approaches aimed at treating or curing these intractable disorders. Stuart will help us deepen our existing academic collaborations, establish additional partnerships and provide strategic guidance on novel technologies to help us in our mission to improve patient outcomes by advancing multiple genetic medicines for neurological disorders for which we may make a tangible, life-altering difference.”
About Neurogene, Inc.
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technologies to develop treatments for diseases not well served by gene therapy. For more information, visit www.neurogene.com.
Sara Green, Ten Bridge Communications